MOESM1 of Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies

Additional file 1. Figures

Description of <i>DPYD</i> variations along with <i>in silico</i> / <i>in vitro</i> functionality.

<p>Description of <i>DPYD</i> variations along with <i>in silico</i> / <i>in vitro</i> functionality.</p

Association of variant combinations and/or DPD phenotype with capecitabine-related toxicity (maximum toxicity grade considering hematotoxicity, digestive and neurotoxicity).

<p>Association of variant combinations and/or DPD phenotype with capecitabine-related toxicity (maximum toxicity grade considering hematotoxicity, digestive and neurotoxicity).</p

CONSORT diagram.

<p>CONSORT diagram.</p

Location of F100L variant within the N-terminal Fe-S cluster containing the alpha helical domain I of the DPD protein.

<p>Protein modeling was performed using UCSF Chimera version 1.8. The pig crystal structure (PDB ID 1gTH) was used as a template. The F100L variant could impair enzyme function by disrupting a conserved residue F100 important for electron transfer via the [4Fe-4S] cluster.</p

New advances in <i>DPYD</i> genotype and risk of severe toxicity under capecitabine - Fig 3

<p>Distribution of pre-treatment plasma UH2/U ratio (A) and Uracil concentrations (B) for the 205 patients with validated phenotypic data, according to <i>DPYD</i> variants of interest: variant *2A (3 heterozygous patients), D949V (3 heterozygous patients), R592W (1 heterozygous patient), D342G (1 heterozygous patient), HapB3 (4 heterozygous patients), 166VV (3 homozygous patients) <i>vs</i> any other variations (185 patients) <i>vs</i> no variation (5 patients). DPD deficiency is reflected by plasma UH2/U decrease or plasma uracil increase. All indicated genotypes were mutually exclusive. Horizontal solid lines indicate median values (10.6 for UH2/U and 9.6 ng/ml for Uracil concentration). Horizontal dotted line on Uracil plot indicates the 91st percentile (16 ng/ml) associated with enhanced grade 3–4 toxicity. Open diamonds indicate patients with toxicity grade 0-1-2 and solid bow ties indicate patients with grade 3–4 toxicity. For variants carried by at least 3 patients, distribution of phenotype was compared between carriers and non-carriers using the non-parametric Mann-Whitney test (* indicates 0.01≤p<0.05 and ** indicates p<0.01).</p

Patient and treatment characteristics (N = 243).

<p>Patient and treatment characteristics (N = 243).</p

Profile of patients with grade 4–5 toxicity.

<p>Profile of patients with grade 4–5 toxicity.</p